Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer
The FEBS Journal · 2023-02 · 290 (3) · 763-779
DOI: 10.1111/febs.16614 ↗At a glance
Journal article in The FEBS Journal, published online on 2022-09-11. Written by Yin Li and 17 co-authors. Institution: State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China. Major MEDLINE topics: Breast Neoplasms, Autophagic Cell Death. Cited 47 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Natural Science Foundation of China, State Key Laboratory of Medicinal Chemical Biology.
Abstract (original language)
Dysregulation of G6PD involved in the pentose phosphate pathway (PPP) is known to promote tumorigenesis. The PPP plays a pivotal role in meeting the anabolic demands of cancer cells. However, the detailed underlying molecular mechanisms of targeting the G6PD‐regulated PPP in breast cancer remain unclear. In this study, we aimed to elucidate the molecular pathways mediating the effects of G6PD on cancer progression. Clinical sample analysis found that the expression of G6PD in breast cancer patients was higher than that in normal controls, and patients with higher G6PD expression had poor survival. Gene knockdown or inhibition of G6PD by 6‐AN in MCF‐7 and MDA‐MB‐231 cells significantly decreased cell viability, migration, and colony formation ability. G6PD enzyme activity was inhibited by 6‐AN treatment, which caused a transient upregulation of ROS. The elevated ROS was independent of cell apoptosis and thus associated with abnormal activated autophagy. Accumulated ROS levels induced autophagic cell death in breast cancer. Inhibition of G6PD suppresses tumour growth in preclinical models of breast cancer. Our results indicate that targeting the G6PD‐regulated PPP could restrain tumours in vitro and in vivo , inhibiting G6PD caused cell death by over‐activating autophagy, therefore leading to inhibited proliferation and tumour formation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
- Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, China.
- Department of Immunology & Wu Lien-Teh Institute & Heilongjiang Provincial Key Laboratory for Infection and Immunity, Harbin Medical University& Heilongjiang Academy of Medical Science, China.
- Department of Breast Surgery, Peking Union Medical College Hospital, Beijing, China.
ORCID profiles: Chenggang Li
Funding
- National Natural Science Foundation of China
- State Key Laboratory of Medicinal Chemical Biology
Cite
APA
Li, Y., Zheng, F., Zhang, Y., Lin, Z., Yang, J., Han, X., Feng, Y., Pei, X., Li, F., Liu, Q., Yan, L., Li, T., Zhang, Y., Li, D., Fu, Z., Wang, C., Sun, Q., & Li, C. (2023). Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer. The FEBS Journal, 290(3), 763-779. https://doi.org/10.1111/febs.16614
Vancouver
Li Y, Zheng F, Zhang Y, Lin Z, Yang J, Han X, et al. Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer. The FEBS Journal. 2023;290(3):763-779. doi:10.1111/febs.16614
BibTeX
@article{Li2023,
author = {Li, Yin and Zheng, Fangxu and Zhang, Yupeng and Lin, Zhoujun and Yang, Juan and Han, Xiao and Feng, Ya and Pei, Xiaolin and Li, Fei and Liu, Qiao and Yan, Lizhong and Li, Tianjiao and Zhang, Yifan and Li, Ding and Fu, Zhenkun and Wang, Changjun and Sun, Qiang and Li, Chenggang},
title = {Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS ‐mediated autophagic cell death in breast cancer},
journal = {The FEBS Journal},
year = {2023},
volume = {290},
number = {3},
pages = {763--779},
doi = {10.1111/febs.16614}
}
EUVIMED